JP2012530253A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012530253A5 JP2012530253A5 JP2012515467A JP2012515467A JP2012530253A5 JP 2012530253 A5 JP2012530253 A5 JP 2012530253A5 JP 2012515467 A JP2012515467 A JP 2012515467A JP 2012515467 A JP2012515467 A JP 2012515467A JP 2012530253 A5 JP2012530253 A5 JP 2012530253A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- sample
- prx4
- antibody
- clinical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 16
- 239000000523 sample Substances 0.000 claims 16
- 102000007456 Peroxiredoxin Human genes 0.000 claims 14
- 108030002458 peroxiredoxin Proteins 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 7
- 208000024891 symptom Diseases 0.000 claims 5
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 206010033645 Pancreatitis Diseases 0.000 claims 3
- 206010040047 Sepsis Diseases 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 208000019622 heart disease Diseases 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 208000017169 kidney disease Diseases 0.000 claims 3
- 230000004770 neurodegeneration Effects 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 238000013517 stratification Methods 0.000 claims 3
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 210000001124 body fluid Anatomy 0.000 claims 2
- 230000009260 cross reactivity Effects 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 238000003748 differential diagnosis Methods 0.000 claims 2
- 208000010643 digestive system disease Diseases 0.000 claims 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims 2
- 239000000284 extract Substances 0.000 claims 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 2
- 238000005259 measurement Methods 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 230000036542 oxidative stress Effects 0.000 claims 2
- 238000004393 prognosis Methods 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 230000003276 anti-hypertensive effect Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- 239000013068 control sample Substances 0.000 claims 1
- 230000035487 diastolic blood pressure Effects 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 230000035488 systolic blood pressure Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09162874.3 | 2009-06-16 | ||
| EP09162874 | 2009-06-16 | ||
| EP09167940 | 2009-08-14 | ||
| EP09167940.7 | 2009-08-14 | ||
| PCT/EP2010/058414 WO2010146064A1 (en) | 2009-06-16 | 2010-06-15 | Diagnostical use of peroxiredoxin 4 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012530253A JP2012530253A (ja) | 2012-11-29 |
| JP2012530253A5 true JP2012530253A5 (enExample) | 2013-01-17 |
Family
ID=42357554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012515467A Pending JP2012530253A (ja) | 2009-06-16 | 2010-06-15 | ペルオキシレドキシン４の診断的使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20120129187A1 (enExample) |
| EP (1) | EP2443148A1 (enExample) |
| JP (1) | JP2012530253A (enExample) |
| CN (1) | CN102482343A (enExample) |
| WO (1) | WO2010146064A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011206049A (ja) | 2010-03-08 | 2011-10-20 | Sumio Sugano | 壊死マーカー及びその用途 |
| CN102346190A (zh) * | 2011-01-24 | 2012-02-08 | 中国人民解放军第三军医大学 | 用于检测生物标本中的过氧化物还原酶ⅳ的双抗夹心elisa试剂盒及其方法与运用 |
| CN102346186B (zh) * | 2011-01-24 | 2015-05-27 | 中国人民解放军第三军医大学 | 用于检测生物标本中的过氧化物还原酶ⅳ抗体的elisa试剂盒及其方法与运用 |
| CN102344916B (zh) * | 2011-01-24 | 2013-08-07 | 中国人民解放军第三军医大学 | 类风湿关节炎特异性抗原 |
| CN103308674B (zh) * | 2012-12-20 | 2018-04-06 | 周继蓉 | 过氧化物还原酶iv的循环免疫复合物及其应用 |
| US10648984B2 (en) * | 2014-04-15 | 2020-05-12 | Cezanne S.A.S. | Immunoassay and antibodies for the detection of chromogranin A |
| CN106093429A (zh) * | 2016-06-02 | 2016-11-09 | 滨州医学院 | 一种检测胃癌组织的试剂盒 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5501969A (en) * | 1994-03-08 | 1996-03-26 | Human Genome Sciences, Inc. | Human osteoclast-derived cathepsin |
| US6255079B1 (en) * | 1995-06-06 | 2001-07-03 | Human Genome Sciences, Inc. | Polynucleotides encoding natural killer cell enhancing factor C |
| US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
| WO2004055519A2 (en) | 2002-12-17 | 2004-07-01 | Sinogenomax Co. Ltd. | Specific markers for pancreatic cancer |
| DE10316583A1 (de) | 2003-04-10 | 2004-10-28 | B.R.A.H.M.S Aktiengesellschaft | Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung |
| JP2005080524A (ja) * | 2003-09-05 | 2005-03-31 | Japan Science & Technology Agency | 前立腺癌マーカポリペプチド、該ポリペプチドに対する抗体、及び該ポリペプチドを利用した前立腺癌の診断方法 |
| EP1628136A1 (en) | 2004-08-19 | 2006-02-22 | B.R.A.H.M.S. Aktiengesellschaft | Method of diagnosis of disease using copeptin |
| JP4840804B2 (ja) * | 2006-01-20 | 2011-12-21 | 学校法人慶應義塾 | 酸化ストレスの判定方法 |
| CN101395473B (zh) * | 2006-03-20 | 2012-09-19 | 阿莱瑞士股份有限公司 | 利用水溶性轭合物的电化学检测方法 |
| WO2007140352A2 (en) * | 2006-05-26 | 2007-12-06 | Invitrogen Corporation | Plasma membrane and secreted cancer biomarkers |
-
2010
- 2010-06-15 US US13/378,460 patent/US20120129187A1/en not_active Abandoned
- 2010-06-15 EP EP10727712A patent/EP2443148A1/en not_active Withdrawn
- 2010-06-15 JP JP2012515467A patent/JP2012530253A/ja active Pending
- 2010-06-15 CN CN2010800265623A patent/CN102482343A/zh active Pending
- 2010-06-15 WO PCT/EP2010/058414 patent/WO2010146064A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2656897T3 (es) | Procedimientos de predicción del riesgo de desarrollar hipertensión | |
| Shin et al. | Phase angle as a marker for muscle health and quality of life in patients with chronic kidney disease | |
| JP2021513077A5 (enExample) | ||
| JP2024028816A (ja) | 腎疾患及び歯周疾患を検出及び診断するための方法及び組成物 | |
| Di Grande et al. | Neutrophil gelatinase-associated lipocalin: a novel biomarker for the early diagnosis of acute kidney injury in the emergency department. | |
| JP2023082094A (ja) | 腎代替療法の管理におけるインスリン様増殖因子結合タンパク質７および組織メタロプロテアーゼ阻害物質２の使用 | |
| JP2020519904A5 (enExample) | ||
| CN109072302A (zh) | 非酒精性脂肪性肝炎的非侵入性诊断 | |
| CN107345970A (zh) | 一种可用于首发精神分裂症诊断的外周血生物标志物 | |
| WO2021185786A1 (en) | Dpp3 in patients infected with coronavirus | |
| KR20160146668A (ko) | Ｍｍｐ-8 활성화 생성물, 이의 결정 및 용도 | |
| JP2020117491A (ja) | 新規抗ウロモジュリン抗体、その抗体を使用した血中ウロモジュリン濃度の測定方法及び測定キット、並びに、そのキットを用いた腎機能の評価方法 | |
| Mo et al. | High mobility group box 1 and homocysteine as preprocedural predictors for contrast-induced acute kidney injury after percutaneous coronary artery intervention | |
| BR112021002281A2 (pt) | pro-adm para prognosticar o risco de uma condição médica requerendo hospitalização em pacientes com sintomas de doença infecciosa | |
| Badanjak | An overview of salivaomics: Oral biomarkers of disease | |
| BR112020004138A2 (pt) | pro-adm como marcador de monitoramento terapêutico para pacientes doentes em estado crítico | |
| CN111413508A (zh) | 尿timp-2和igfbp-7在制备用于诊断脓毒症急性肾损伤的生物标记物中的用途 | |
| Christ-Crain et al. | Procalcitonin: Importance for the diagnosis of bacterial infections | |
| Schiestl et al. | Development and Analytical Characterization of GP2017: A Proposed Adalimumab Biosimilar: 628 | |
| JP2026505216A (ja) | Ｔ１４ペプチドを使用してアルツハイマー病を診断するための側方流動デバイス | |
| CN117761309A (zh) | 组织蛋白酶b在制备用于诊断和/或监测慢性阻塞性肺疾病的急性加重的试剂盒中的应用 | |
| JP6555711B2 (ja) | 非解離性大動脈瘤の疾患活動性の判定方法 | |
| JP2015503106A5 (enExample) | ||
| Stadler et al. | Serial measurement of nitrite and xanthine oxidase (XO) to assess antimicrobial pharmacodynamics (PD) and treatment efficacy in urinary tract infections (UTIs): A proof-of-concept for personalized antimicrobial therapy | |
| RU2482485C2 (ru) | Способ прогнозирования достижения компенсации сахарного диабета 2 типа |